

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Posaconazole

August 27, 2024

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Posaconazole

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision						
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, finerenone, lurasidone hydrochloride, blonanserin, triazolam, rivaroxaban</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, finerenone, <u>azelnidipine, olmesartan medoxomil/azelnidipine</u>, lurasidone hydrochloride, blonanserin, triazolam, rivaroxaban</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/ risk factors</th></tr><tr><td><u>Azelnidipine</u> <u>Olmesartan medoxomil/azelnidipine</u></td><td>The effect of <u>azelnidipine</u> may be <u>enhanced</u>.</td><td>The plasma <u>concentration of azelnidipine</u> is <u>expected to rise due to the inhibition of CYP3A4 by co-administration with posaconazole</u>.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/ risk factors	<u>Azelnidipine</u> <u>Olmesartan medoxomil/azelnidipine</u>	The effect of <u>azelnidipine</u> may be <u>enhanced</u> .	The plasma <u>concentration of azelnidipine</u> is <u>expected to rise due to the inhibition of CYP3A4 by co-administration with posaconazole</u> .
Drugs	Signs, symptoms, and treatment	Mechanism/ risk factors					
<u>Azelnidipine</u> <u>Olmesartan medoxomil/azelnidipine</u>	The effect of <u>azelnidipine</u> may be <u>enhanced</u> .	The plasma <u>concentration of azelnidipine</u> is <u>expected to rise due to the inhibition of CYP3A4 by co-administration with posaconazole</u> .					

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS